Prescription medicine
Florbetapir f 18 Brand names: Amyvid
Florbetapir f 18 (Amyvid) is a prescription medicine with an FDA approval on record since 2012. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the florbetapir f 18 FDA label on DailyMed (effective December 11, 2025, Eli Lilly and Company); the NDA 202008 record on Drugs@FDA; every florbetapir f 18 label on DailyMed.
Highlights of the record
FDA label of December 11, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageAMYVID is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products AMYVID is a radioactive diagnostic
Forms and strengths
Injection (solution).
On the market
- Earliest approval on file
- April 6, 2012 Amyvid, Avid Radiopharms Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- April 30, 2027 Amyvid injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 113 through July 30, 2026
What is florbetapir f 18 used for?
From the label: indications and usageAMYVID is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products AMYVID is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products […]
FDA pharmacologic class: Radioactive Diagnostic Agent.
Source: FDA drug label (Amyvid), NDA202008 (Avid Radiopharms Inc), as published by Eli Lilly and Company, effective December 11, 2025 (SPL set bb5a5043-0f51-11df-8a39-0800200c9a66), via openFDA; the full label on DailyMed
Is there a generic for florbetapir f 18 (Amyvid)?
No generic florbetapir f 18 is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 2 patents for Amyvid injection: the compound patent runs to April 30, 2027. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2012 earliest approval on file
- 2027 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for florbetapir f 18?
The FDA Adverse Event Reporting System holds 113 reports that list florbetapir f 18 among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1 are coded as a death and 12 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other radioactive diagnostic agents
- the pharmacologic class, with prices and generics
- Florbetapir f 18 side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other